UNITED STATES, WASHINGTON (OBSERVATORY) — A new class of antidiabetic drugs – sodium glucose cotransporter inhibitors reduce blood glucose concentration due to a decrease in glucose reabsorption in the proximal renal tubules independent of insulin, that is, by stimulating its excretion in the urine.
In addition to the benefits of SGLT2 inhibitors identified in previous clinical trials, researchers at the Karolinska Institute report that these diabetes drugs reduced their risk of heart failure by 34% and premature death by 20%.
These findings are based on a study of data from approximately 21 thousand patients with type 2 diabetes who were treated with two SGLT2 inhibitors from April 2013 to December 2016. Experts compared the effects of treatment with SGLT2 inhibitors and DPP4 inhibitors in favor of the former.
Scientists acknowledge that their results mainly relate to dapagliflozin, the type of SGLT2 inhibitor most common in Scandinavia during the study period. However, another SGLT2 inhibitor, canagliflozin, marketed under the brand name Invokana, also protects the kidneys and heart and reduces the risk of death.
This article is written and prepared by our foreign editors writing for OBSERVATORY NEWS from different countries around the world – material edited and published by OBSERVATORY staff in our newsroom.
OBSERVATORY NEWS — Breaking news source, real-time coverage of the world’s events, life, politics, business, finance, economy, markets, war and conflict zones.
Contact us: [email protected]
Stay connected with News Observatory and Observatory Newsroom, also with our online services and never lost the breaking news stories happening around the world.
We are NEWS OBSERVATORY — the only funding and support we get from people – we are categorically not funded by any political party, any government somewhere or from any grouping that supports certain interests – the only support that makes OBSERVATORY possible came from you.